Karyopharm Therapeutics Stock Revenue
| KPTI Stock | USD 0.59 0.04 7.03% |
Karyopharm Therapeutics fundamentals help investors to digest information that contributes to Karyopharm Therapeutics' financial success or failures. It also enables traders to predict the movement of Karyopharm Stock. The fundamental analysis module provides a way to measure Karyopharm Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Karyopharm Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 146 M | 153.3 M |
Karyopharm | Revenue |
Karyopharm Therapeutics Company Revenue Analysis
Karyopharm Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Karyopharm Therapeutics Revenue | 146.03 M |
Most of Karyopharm Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Karyopharm Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Karyopharm
Projected quarterly revenue analysis of Karyopharm Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Karyopharm Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Karyopharm Therapeutics' stock price.
Karyopharm Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Karyopharm Therapeutics is extremely important. It helps to project a fair market value of Karyopharm Stock properly, considering its historical fundamentals such as Revenue. Since Karyopharm Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Karyopharm Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Karyopharm Therapeutics' interrelated accounts and indicators.
| 0.62 | 0.02 | 0.03 | 0.62 | -0.1 | ||
| 0.62 | -0.5 | -0.38 | 0.97 | 0.46 | ||
| 0.02 | -0.5 | 0.25 | -0.5 | -0.46 | ||
| 0.03 | -0.38 | 0.25 | -0.39 | -0.44 | ||
| 0.62 | 0.97 | -0.5 | -0.39 | 0.49 | ||
| -0.1 | 0.46 | -0.46 | -0.44 | 0.49 |
Click cells to compare fundamentals
Karyopharm Revenue Historical Pattern
Today, most investors in Karyopharm Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Karyopharm Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Karyopharm Therapeutics revenue as a starting point in their analysis.
Karyopharm Therapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Karyopharm Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Karyopharm Therapeutics reported 146.03 M of revenue. This is 98.09% lower than that of the Biotechnology sector and 80.34% lower than that of the Health Care industry. The revenue for all United States stocks is 98.45% higher than that of the company.
Karyopharm Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karyopharm Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics of similar companies.Karyopharm Therapeutics is currently under evaluation in revenue category among its peers.
Karyopharm Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Karyopharm Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Karyopharm Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Karyopharm Therapeutics' value.| Shares | Cam Group Holding A/s | 2024-09-30 | 1.5 M | Jpmorgan Chase & Co | 2024-09-30 | 1.4 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-09-30 | 1.3 M | Deutsche Bank Ag | 2024-09-30 | 1.3 M | Millennium Management Llc | 2024-09-30 | 1.3 M | Renaissance Technologies Corp | 2024-09-30 | 1.2 M | Kennedy Capital Management Inc | 2024-09-30 | 1.2 M | Ubs O'connor Llc | 2024-09-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 7.7 M | Eversept Partners, Llc | 2024-09-30 | 5.5 M |
Karyopharm Fundamentals
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.68) % | ||||
| Current Valuation | 142.09 M | ||||
| Shares Outstanding | 126.19 M | ||||
| Shares Owned By Insiders | 6.21 % | ||||
| Shares Owned By Institutions | 48.20 % | ||||
| Number Of Shares Shorted | 18.92 M | ||||
| Price To Earning | (3.90) X | ||||
| Price To Book | 12.05 X | ||||
| Price To Sales | 0.52 X | ||||
| Revenue | 146.03 M | ||||
| Gross Profit | 151.86 M | ||||
| EBITDA | (118.42 M) | ||||
| Net Income | (143.1 M) | ||||
| Cash And Equivalents | 170.85 M | ||||
| Cash Per Share | 2.14 X | ||||
| Total Debt | 177.02 M | ||||
| Debt To Equity | 2.59 % | ||||
| Current Ratio | 3.88 X | ||||
| Book Value Per Share | (1.27) X | ||||
| Cash Flow From Operations | (92.72 M) | ||||
| Short Ratio | 19.48 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 4.5 | ||||
| Number Of Employees | 325 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 77.76 M | ||||
| Total Asset | 240.44 M | ||||
| Retained Earnings | (1.49 B) | ||||
| Working Capital | 164.44 M | ||||
| Current Asset | 130.25 M | ||||
| Current Liabilities | 14.95 M | ||||
| Net Asset | 240.44 M |
About Karyopharm Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Karyopharm Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Karyopharm Therapeutics Piotroski F Score and Karyopharm Therapeutics Altman Z Score analysis. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.